-
1
-
-
0021281324
-
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
-
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.
-
(1984)
Nature
, vol.307
, pp. 521-527
-
-
Downward, J.1
Yarden, Y.2
Mayes, E.3
Scrace, G.4
Totty, N.5
Stockwell, P.6
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
3
-
-
0026502860
-
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
-
Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
-
(1992)
Br J Cancer
, vol.65
, pp. 118-121
-
-
Wright, C.1
Nicholson, S.2
Angus, B.3
Sainsbury, J.R.4
Farndon, J.5
Cairns, J.6
-
4
-
-
0026625217
-
Prognostic importance of c-erbB-2 expression in breast cancer
-
International (Ludwig) Breast Cancer Study Group
-
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1049-1056
-
-
Gusterson, B.A.1
Gelber, R.D.2
Goldhirsch, A.3
Price, K.N.4
Save-Soderborgh, J.5
Anbazhagan, R.6
-
5
-
-
0026610881
-
Humanization of an anti-p185HER2 antibody for human cancer therapy
-
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
Ridgway, J.B.4
Henner, D.5
Wong, W.L.6
-
6
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
-
(1996)
J Clin Oncol
, vol.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
Baughman, S.4
Benz, C.C.5
Dantis, L.6
-
7
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr. CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr., C.E.5
Davidson, N.E.6
-
8
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer
-
Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
9
-
-
22144441093
-
-
On behalf of NCCTG, ECOG, SWOG, CALGB
-
Perez EA, Suman VJ, Davidson N, Martino S. Kaufman. On behalf of NCCTG, ECOG, SWOG, CALGB. Proc Am Soc Clin Oncol 2005; 24: 556.
-
(2005)
Proc Am Soc Clin Oncol
, vol.24
, pp. 556
-
-
Perez, E.A.1
Suman, V.J.2
Davidson, N.3
Kaufman, M.S.4
-
10
-
-
33751013663
-
-
on Behalf of NCCTG, ECOG, SWOG, CALGB. Proc ECCO
-
Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB. NCCTG N9831 Update from ASCO 2005. Proc ECCO, 2005.
-
(2005)
NCCTG N9831 Update from ASCO 2005
-
-
Perez, E.A.1
Suman, V.J.2
Davidson, N.3
Martino, S.4
Kaufman, P.5
-
11
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
12
-
-
22344446208
-
Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer given as first-line treatment: Results of a randomized phase II trial (M77001)
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer given as first-line treatment: results of a randomized phase II trial (M77001). J Clin Oncol 2005; 23: 4265-74.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
-
13
-
-
26844559765
-
Trastuzumab in the treatment of breast cancer
-
Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Mol 2005; 353: 1734-6.
-
(2005)
N Engl J Mol
, vol.353
, pp. 1734-1736
-
-
Hortobagyi, G.1
-
14
-
-
33344478381
-
Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer trial
-
Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer trial. N Engl J Med 2006; 354: 809-20.
-
(2006)
N Engl J Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.-L.2
Bono, P.3
Alanko, T.4
Kataja, V.5
Asola, R.6
-
15
-
-
33645720799
-
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study
-
abstract
-
Slamon D. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 91: 1[abstract].
-
(2005)
Breast Cancer Res Treat
, vol.91
, pp. 1
-
-
Slamon, D.1
-
16
-
-
0033118889
-
Inhibition effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of breast cancers
-
Pergam M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibition effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of breast cancers. Oncogene 1999; 18: 2241-51.
-
(1999)
Oncogene
, vol.18
, pp. 2241-2251
-
-
Pergam, M.1
Hsu, S.2
Lewis, G.3
Pietras, R.4
Beryt, M.5
Sliwkowski, M.6
-
17
-
-
31444451572
-
Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
-
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67.
-
(2006)
Br J Cancer
, vol.94
, pp. 259-267
-
-
Arnould, L.1
Gelly, M.2
Penault-Llorca, F.3
Benoit, L.4
Bonnetain, F.5
Migeon, C.6
-
18
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
19
-
-
0036099675
-
ErbB2 is essential in the prevention of dilated cardiomyopathy
-
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-65.
-
(2002)
Nat Med
, vol.8
, pp. 459-465
-
-
Crone, S.A.1
Zhao, Y.Y.2
Fan, L.3
Gu, Y.4
Minamisawa, S.5
Liu, Y.6
-
20
-
-
33746326116
-
Severity of cardiovascular disease in women: Relation with exposure to endogenous estrogen
-
Saltiki K, Doukas C, Kanakakis J, Anastasiou H, Mantzou E, Alevizaki M. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. Maturitas 2006; 55: 51-7.
-
(2006)
Maturitas
, vol.55
, pp. 51-57
-
-
Saltiki, K.1
Doukas, C.2
Kanakakis, J.3
Anastasiou, H.4
Mantzou, E.5
Alevizaki, M.6
-
21
-
-
33750990973
-
-
Collectif. Paris: Ed Inserm
-
Collectif. France: portrait social. Paris: Ed Inserm, 2006.
-
(2006)
France: Portrait Social
-
-
-
22
-
-
0012643984
-
Phase III comparative study of trastuzumab and paclitaxel with or without carboplatin in patients with Her-2/neu positive advanced breast cancer
-
Robert N, Leyland-Jones B, Asmar L, Belt R, Illegbodu D, Loesch D, et al. Phase III comparative study of trastuzumab and paclitaxel with or without carboplatin in patients with Her-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76: S7.
-
(2002)
Breast Cancer Res Treat
, vol.76
-
-
Robert, N.1
Leyland-Jones, B.2
Asmar, L.3
Belt, R.4
Illegbodu, D.5
Loesch, D.6
-
23
-
-
33749629577
-
Adjuvant radiotherapy and trastuzumab, in stage I-IIA breast cancer: Toxicity and data from North Central Cancer Treatment Group phase III trial N9831
-
abstract
-
Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, et al. Adjuvant radiotherapy and trastuzumab, in stage I-IIA breast cancer: toxicity and data from North Central Cancer Treatment Group phase III trial N9831. Proc Clin Oncol 2006; 24: 523 [abstract].
-
(2006)
Proc Clin Oncol
, vol.24
, pp. 523
-
-
Halyard, M.Y.1
Pisansky, T.M.2
Solin, L.J.3
Marks, L.B.4
Pierce, L.J.5
Dueck, A.6
-
24
-
-
33750952036
-
Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities
-
abstract
-
Belkacemi Y, Gligorov J, Laharie-Mineur O, Marsiglia H, Ozsahin MO, Azria D. Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities. Proc J Clin Oncol 2006; 24: 630 [abstract].
-
(2006)
Proc J Clin Oncol
, vol.24
, pp. 630
-
-
Belkacemi, Y.1
Gligorov, J.2
Laharie-Mineur, O.3
Marsiglia, H.4
Ozsahin, M.O.5
Azria, D.6
-
25
-
-
4744342405
-
Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: Practice is culture driven rather than evidence based
-
Taghian A, Jagsi R, Makris A, Goldberg S, Ceilley, Grignon L, et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol 2004; 60: 706-14.
-
(2004)
Int J Radiat Oncol Biol
, vol.60
, pp. 706-714
-
-
Taghian, A.1
Jagsi, R.2
Makris, A.3
Goldberg, S.4
Ceilley5
Grignon, L.6
-
26
-
-
0346874162
-
Anti-EGF receptors and radiation therapy: Current translational research and early clinical trials
-
Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, et al. Anti-EGF receptors and radiation therapy: current translational research and early clinical trials. Bull Cancer 2003; 90: 202-12.
-
(2003)
Bull Cancer
, vol.90
, pp. 202-212
-
-
Azria, D.1
Larbouret, C.2
Robert, B.3
Culine, S.4
Ychou, M.5
Verrelle, P.6
-
27
-
-
0033559619
-
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
-
Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347-55.
-
(1999)
Cancer Res
, vol.59
, pp. 1347-1355
-
-
Pietras, R.J.1
Poen, J.C.2
Gallardo, D.3
Wongvipat, P.N.4
Lee, H.J.5
Slamon, D.J.6
-
28
-
-
33750990671
-
Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer
-
abstract
-
Bellon JR, Gover MT, Burstein HJ, Harris JR, Harris LN. Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol 2005; 63: 91 [abstract].
-
(2005)
Int J Radiat Oncol Biol
, vol.63
, pp. 91
-
-
Bellon, J.R.1
Gover, M.T.2
Burstein, H.J.3
Harris, J.R.4
Harris, L.N.5
-
29
-
-
17144371333
-
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
-
Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-71.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2162-2171
-
-
Baselga, J.1
Carbonell, X.2
Castaneda-Soto, N.J.3
Clemens, M.4
Green, M.5
Harvey, V.6
-
30
-
-
0035160313
-
Cardiotoxicity in signal transduction therapeutics: Erb2 antibodies and the heart
-
Schneider JW, Chang AW, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erb2 antibodies and the heart. Semin Oncol 2001; 28: 18-26.
-
(2001)
Semin Oncol
, vol.28
, pp. 18-26
-
-
Schneider, J.W.1
Chang, A.W.2
Rocco, T.P.3
-
31
-
-
0034471831
-
Myocyte survival patways and cardiomyopathy: Implications of trastuzumab cardiotoxicity
-
Chien KR. Myocyte survival patways and cardiomyopathy: implications of trastuzumab cardiotoxicity. Semin Oncol 2001; 27: 9-14.
-
(2001)
Semin Oncol
, vol.27
, pp. 9-14
-
-
Chien, K.R.1
-
32
-
-
0037007076
-
Modulation of anthracyclines-induced myofibrillar disarray in rat ventricular myocytes by neuroglin 1-beta and anti-erb2: Potential mechanism for trastuzumab-induced cardiotoxicity
-
Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracyclines-induced myofibrillar disarray in rat ventricular myocytes by neuroglin 1-beta and anti-erb2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105: 1551-4.
-
(2002)
Circulation
, vol.105
, pp. 1551-1554
-
-
Sawyer, D.B.1
Zuppinger, C.2
Miller, T.A.3
Eppenberger, H.M.4
Suter, T.M.5
-
33
-
-
0141576783
-
Meeting highlights: Update international expert consensus on the primary therapy of early breast cancer
-
Goldhirsch A, Wood WC, Gelber RD. Coates AS, Thurlimann B, Senn HJ. Meeting highlights: update international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3357-3365
-
-
Goldhirsch, A.1
Wood, W.C.2
Gelber, R.D.3
Coates, A.S.4
Thurlimann, B.5
Senn, H.J.6
-
34
-
-
33750973821
-
Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H)
-
abstract
-
Geyer CE, Bryant JL, Romond EH, Ewer MS, Keefe DL, Shannon RP, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H). Proc J Clin Oncol 2006; 24: 581 [abstract].
-
(2006)
Proc J Clin Oncol
, vol.24
, pp. 581
-
-
Geyer, C.E.1
Bryant, J.L.2
Romond, E.H.3
Ewer, M.S.4
Keefe, D.L.5
Shannon, R.P.6
-
35
-
-
33344458106
-
Herceptin and the heart: Molecular modifier of cardiac failure
-
Chien KR. Herceptin and the heart: molecular modifier of cardiac failure. N Engl J Med 2006; 354: 789-90.
-
(2006)
N Engl J Med
, vol.354
, pp. 789-790
-
-
Chien, K.R.1
-
36
-
-
0037606000
-
Initial clinical experience with moderate deep-inspiration breath hold using an active breathing control device in the treatment of patients with left-sided breast cancer using external beam radiation therapy
-
Remouchamps VM, Letts N, Vicini FA, Sharpe MB, Kestin LL, Chen PY, et al. Initial clinical experience with moderate deep-inspiration breath hold using an active breathing control device in the treatment of patients with left-sided breast cancer using external beam radiation therapy. Int J Radiat Oncol Biol Phys 2003; 56: 704-15.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, pp. 704-715
-
-
Remouchamps, V.M.1
Letts, N.2
Vicini, F.A.3
Sharpe, M.B.4
Kestin, L.L.5
Chen, P.Y.6
-
37
-
-
20044371012
-
MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer
-
Krauss DJ, Kestin LL, Raff G. MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1243-50.
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.61
, pp. 1243-1250
-
-
Krauss, D.J.1
Kestin, L.L.2
Raff, G.3
-
38
-
-
10044286214
-
Radiation toxicity to the heart: Physiopathology and clinical data
-
Giraud P, Cosset JM. Radiation toxicity to the heart: physiopathology and clinical data. Bull Cancer 2004; 91: 147-53.
-
(2004)
Bull Cancer
, vol.91
, pp. 147-153
-
-
Giraud, P.1
Cosset, J.M.2
-
39
-
-
10044264624
-
Anthracycline-induced cardiotoxicity
-
Petit T. Anthracycline-induced cardiotoxicity. Bull Cancer 2004; 91: 159-65.
-
(2004)
Bull Cancer
, vol.91
, pp. 159-165
-
-
Petit, T.1
|